Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Radiopharm Theranostics Limited before investing.

In this article, we go over a few key elements for understanding Radiopharm Theranostics Limited’s stock price such as:

• Radiopharm Theranostics Limited’s current stock price and volume
• Why Radiopharm Theranostics Limited’s stock price changed recently
• Upgrades and downgrades for RADX from analysts
• RADX’s stock price momentum as measured by its relative strength

About Radiopharm Theranostics Limited (RADX)

Before we jump into Radiopharm Theranostics Limited’s stock price, history, target price and what caused it to recently , let’s take a look at some background.

Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs. The company develops several products, including RAD101, a pivalate brain metastasis diagnostic; RAD102, a pivalate therapeutic; RAD201a, a Nano-mAb HER-2 breast diagnostic; RAD202, a Nano-mAb HER-2 breast therapeutic; RAD203, a Nano-mAb PDL1 non-small cell lung diagnostic; and RAD204, a Nano-mAb PDL1 non-small cell lung therapeutic. Additionally, it is developing RAD301 and RAD302, which are Avß6-Integrin pancreatic diagnostic and therapeutic products; RAD401, a PSA-mAb prostate cancer diagnostic; RAD402, a PSA-mAb prostate cancer therapeutic; RAD601, a PTPµ glioblastoma diagnostic; and RAD602, a PTPµ glioblastoma therapeutic. The company has a strategic agreement with Lantheus Holdings, Inc. to advance the clinical development of radiopharmaceuticals. The company was incorporated in 2021 and is based in Carlton, Australia.

Want to learn more about Radiopharm Theranostics Limited’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Radiopharm Theranostics Limited.

Radiopharm Theranostics Limited’s Stock Price as of Market Close

As of September 03, 2026, 11:59 AM, CST, Radiopharm Theranostics Limited’s stock price was $2.160.

Radiopharm Theranostics Limited is 0% from its previous closing price of $2.160.

During the last market session, Radiopharm Theranostics Limited’s stock traded between $2.050 and $2.200. Currently, there are approximately 1,713.01 million shares outstanding for Radiopharm Theranostics Limited.

Radiopharm Theranostics Limited’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Radiopharm Theranostics Limited Stock Price History

Radiopharm Theranostics Limited’s (RADX) price is currently down 5.26% so far this month.

During the month of September, Radiopharm Theranostics Limited’s stock price has reached a high of $2.300 and a low of $2.050.

Over the last year, Radiopharm Theranostics Limited has hit prices as high as $16.250 and as low as $2.044. Year to date, Radiopharm Theranostics Limited’s stock is down 58.62%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Radiopharm Theranostics Limited Stock’s Price to ?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of September 02, 2026, there were analysts who downgraded Radiopharm Theranostics Limited’s stock and analysts who upgraded over the last month.

Additionally, you'll want to evaluate Radiopharm Theranostics Limited’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Radiopharm Theranostics Limited’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Radiopharm Theranostics Limited’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Radiopharm Theranostics Limited (RADX) by visiting AAII Stock Evaluator.

Relative Price Strength of Radiopharm Theranostics Limited

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of September 02, 2026, Radiopharm Theranostics Limited has a weighted four-quarter relative price strength of -27.40%, which translates to a Momentum Score of 8 and is considered to be Very Weak.

Want to learn more about how Radiopharm Theranostics Limited is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Radiopharm Theranostics Limited Stock Price: Bottom Line

As of September 3, 2026, Radiopharm Theranostics Limited’s stock price is $2.160, which is 0% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Radiopharm Theranostics Limited stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.